Clinical-stage biotech Neurizon Therapeutics has reported encouraging new rodent preclinical pharmacokinetic (PK) data for its lead candidate NUZ-001, showing it effectively crosses the blood-brain ...

The first Tomisich explained was “reproducible, precision fabrication on scale”, meaning Trajan’s components must have ...

Tasmanian Senator Jacqui Lambie has slammed the NDIS over its Annual Pricing Review, calling it a “betrayal.” The review was ...

These shares have been named by brokers as buys for income investors. Let's see what they offer. The post Buy Fortescue and ...

A new scholarship in the name of one of the University of Tasmania's most innovative and inspirational alumni will support ...

A multi-million dollar innovation fund is expected to make Australia's most populous state a more attractive place to invest ...

Disability care for Australians outside capital cities is at risk amid a major shake-up in NDIS funding, with providers ...

Kellie Finlayson has given a heartbreaking insight into her terminal cancer battle in her new book. The brave mum, who is ...

This Deafblind Awareness week (June 23 to June 29), leading Deafblind service, advocacy and community organisations are urgently asking for a ...

Allied health services like physiotherapy can be life-changing for NDIS participants, but new government pricing arrangements ...

According to a new study, combining exercise with omega-3 supplements reduced inflammation and, thereby, the severity of a ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...